Mendus (OMX: IMMU)

Last close As at 14/01/2025

SEK8.00

−0.22 (−2.68%)

Market capitalisation

SEK414m

Mendus is a clinical-stage immunoncology (IO) company based in Sweden and the Netherlands. The company specialises in allogeneic dendritic cell biology and currently has two lead, cell-based, off-the-shelf therapies for haematological and solid tumours.

Latest Insights

View More

Healthcare | Update

Mendus — Regulatory endorsement supports vididencel focus

Healthcare | edison tv

Mendus – executive interview

Healthcare | Flash note

Mendus — Vididencel shines in ALISON trial (ovarian cancer)

Healthcare | Outlook

Mendus — Gearing up for the pivotal stages of development

Mendus_resized

Sector

Healthcare

Equity Analyst

Jyoti Prakash

Jyoti Prakash, CFA

Analyst, Healthcare

Key Management

  • Alex Karlsson-Parra

    CSO

  • Erik Manting

    CEO

  • Jeroen Rovers

    CMO

  • Leopold Bertea

    CTO

  • Lotta Ferm

    CFO

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free